Core Insights - Targeted protein degradation is an emerging field in drug development, with over 10 years of experience from the company [1] - The company is based in San Francisco and leverages scientific research from UCSF and Berkeley [1] - Targeted protein degraders are small molecules that can be taken orally to remove disease-causing proteins from cells [2] Industry Context - The development of targeted protein degradation is positioned alongside major breakthroughs in drug development, such as antibodies and nucleic acid-based therapies [2] - The primary goal of therapeutics has been to specifically target disease-causing proteins, which is now achievable through targeted protein degradation [2]

Core Insights - The discussion focuses on targeted protein degradation as an evolving therapeutic modality that offers advantages over traditional therapies like antibodies and nucleic acid-based treatments [2][3]. Company Overview - Nurix is positioned within the landscape of therapeutics, emphasizing the effectiveness of targeted protein degradation in removing whole proteins and multiple classes of proteins [3][4]. - The company highlights the benefits of its small molecule approach, which allows for oral administration and once-a-day dosing [3]. Industry Context - The presentation contrasts targeted protein degradation with existing modalities, noting that while antibodies and nucleic acid-based therapies have been successful, they come with certain limitations [2][4]. - The potential for targeted protein degraders to achieve antibody-like efficacy while being more convenient to administer is underscored [4].

Group 1 - The discussion focuses on targeted protein degradation as an evolving therapeutic modality, highlighting its place among successful treatments like antibodies and nucleic acid-based therapies [2][3] - Targeted protein degraders represent a small molecule approach that can effectively remove entire proteins, offering advantages such as oral administration and once-a-day dosing [3][4] - This method is positioned as having antibody-like or biologic-like efficacy, potentially surpassing the effectiveness of traditional nucleic acid-based therapies and antibodies [4]

Core Insights - The conference is hosted by Morgan Stanley, featuring Nurix with CEO Arthur Sands presenting the company's strategic priorities [1][2] Company Overview - Nurix is currently focusing on its strategic priorities and overall company status, as highlighted by the CEO during the conference [2]

Company Overview - Nurix is being hosted at a conference by Morgan Stanley, with Arthur Sands serving as the President and CEO [1] - The conference aims to discuss the company's current standing and strategic priorities [2]

Summary of Nurix Therapeutics FY Conference Call Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Date**: September 10, 2025 - **Key Speaker**: Arthur T. Sands, President and CEO Core Industry and Company Insights Pipeline and Programs - Nurix is entering pivotal studies for its lead program, Bexobrutide (BexDeg), targeting chronic lymphocytic leukemia (CLL) [2] - The company is planning Phase 2 and 3 studies for BexDeg, with recent design considerations disclosed for the Phase 3 study [2][20] - Other programs include NX-2127 and NX-1607, focusing on aggressive lymphomas and immuno-oncology targets, respectively [2][3] - The company has a partnership with Sanofi for a STAT6 degrader and with Gilead for an IRAK4 degrader, both in IND-enabling studies [3][54] Platform and Technology - Nurix's platform is based on E3 ligases and has evolved to include a DEL-AI platform for ligand discovery, allowing for rapid development across oncology and inflammation [5][6] - The platform enables the development of degrader antibody conjugates (DACs), with a partnership with Pfizer [7] Safety and Efficacy of BexDeg - BexDeg has shown no drug-related atrial fibrillation above background levels, indicating a favorable cardiovascular profile compared to other BTK inhibitors [18] - The design of BexDeg aims for high selectivity and potency, which is expected to translate into better efficacy and safety [14] Pivotal Trial Design - The pivotal trial for BexDeg includes a single-arm study for accelerated approval in a third-line plus population, with a randomized control trial planned as a confirmatory study [20][21] - Key endpoints for the accelerated approval include overall response rate (ORR) and progression-free survival (PFS), with an observed ORR of about 80% in earlier trials [22][23] - The market opportunity for the third-line plus patient population is estimated to be between 8,000 to 10,000 patients in the U.S., with significant revenue potential [25] Future Aspirations - Nurix is considering combination therapies for earlier lines of treatment, with plans for a Phase 1B/2 study combining BexDeg with venetoclax and anti-CD20 antibodies [36] - The company is currently self-funding its studies but is open to partnerships for future combination studies [38] Financial Position - Nurix has a cash runway extending into the first half of 2027, with approximately $485 million in cash as of the last quarter [61] Additional Insights - The company is actively participating in upcoming medical conferences to present data on its various programs, including ESMO and ASH [42][45] - The STAT6 program with Sanofi is expected to enter healthy volunteer studies by 2026, pending Sanofi's timeline [56] This summary encapsulates the key points discussed during the conference call, highlighting Nurix Therapeutics' strategic priorities, pipeline developments, and market opportunities.

Nurix Therapeutics (NasdaqGM:NRIX) 2025 Conference September 09, 2025 10:50 AM ET Company ParticipantsArthur Sands - President, CEO, and Board DirectorConference Call ParticipantsBrian Skorney - Senior Biotech AnalystBrian SkorneyMorning, everyone. Thank you for joining our next session. I'm Brian Skorney. I'm one of Baird's Senior Biotech Analysts. I'm very happy to have with us presenting Nurix. It's a company that I cover. I'm very excited about the working in the protein degradation space. They have a l ...

Nurix Therapeutics (NasdaqGM:NRIX) FY Conference September 08, 2025 01:30 PM ET Company ParticipantsArthur Sands - CEO, President & DirectorConference Call ParticipantsRobert Burns - MD & Senior Healthcare AnalystRobert BurnsHi. Welcome to our our fireside chat with NeurIX. I am Rob Perns, managing director and senior biotech analyst at HC Wainwright, and I'm joined by Arthur Sands, the CEO of NeurIX. Arthur, thank you joining us today.Arthur SandsRob, thank you for having us.Robert BurnsNo problem. So I un ...

Financial Data and Key Metrics Changes - The company reported an overall objective response rate of 80% across all patients in the trial, indicating strong efficacy of the drug [13] - The market for bexabrutinib is currently estimated at $2 billion per year, with forecasts suggesting growth to $5 billion per year [18] Business Line Data and Key Metrics Changes - Bexabrutinib is positioned as the first degrader in its category, addressing resistance mutations in BTK inhibitors, which have generated sales of approximately $9 billion to $10 billion [9][10] - The company is also developing an IRAK4 degrader in collaboration with Gilead and a STAT6 degrader with Sanofi, targeting undruggable categories with significant potential [6][48] Market Data and Key Metrics Changes - The Phase III trial will be conducted in 20 to 30 countries, enrolling 400 to 500 patients, maximizing enrollment opportunities across geographies [16] - The third-line market, where the company has generated data, is valued between $1 billion and $2.5 billion [18] Company Strategy and Development Direction - The company aims to establish bexabrutinib as a significant player in the second-line treatment market, with ambitions for first-line treatment in combination therapies [18][33] - The strategy includes a focus on both oncology and autoimmune diseases, with plans to explore multiple sclerosis and dermatology as potential areas for expansion [43][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety profile of bexabrutinib, noting no dose-limiting toxicities or new arrhythmias observed in trials [13] - The company is optimistic about rapid enrollment in the Phase II trial due to enthusiasm from investigators and the promising results seen to date [28] Other Important Information - The company has invested over $250 million in the IRAK4 and STAT6 programs, indicating a strong commitment to these projects [48] - Future updates on the broader pipeline and other programs are expected in the fall [63] Q&A Session Summary Question: How should we think about the breakdown in terms of geography and the relevant investigator choice for the standard of care? - The company anticipates variations in treatment choices across geographies, with pirtobrutinib being primarily selected in the U.S. and Europe, while bendamustine-rituximab is more common outside these regions [20] Question: How do you think about the powering of the trial and expectations from the investigator choice arm? - The trial is powered for 400 to 500 patients, and management believes it will be well-powered to demonstrate superiority of bexabrutinib over the control arm [23] Question: What drove the decision for this trial design compared to competitors? - The design is capital efficient, allowing for a streamlined approach to achieve first approval while maintaining the potential for expansion in the future [25] Question: What are the expectations for enrollment timing for the Phase II and Phase III trials? - Enrollment for the Phase II trial is expected to take about a year, while the Phase III trial will take longer, with no specific forecast yet [28][29] Question: Is there a plan to bring in a partner to help with development costs? - The company intends to move forward independently for now, but partnerships could be considered in the future to maximize value [31] Question: How do you see differentiation between your molecules and competitors? - Differentiation will likely emerge based on safety profiles and off-target effects, which are harder to predict but crucial for long-term success [34] Question: What is the strategy for BexDeg in non-Hodgkin lymphoma and autoimmune diseases? - The company sees significant monotherapy opportunities in Waldenstrom's and plans to explore broader applications in autoimmune diseases, leveraging the advantages seen in oncology [36][39] Question: What updates can we expect for the IRAK4 and STAT6 programs? - The IRAK4 program is currently in healthy volunteer studies, while the STAT6 program has shown promising preclinical results, with both expected to advance in collaboration with Gilead and Sanofi [49][51]

Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and ...